• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺类癌肿瘤和错构瘤的生长速度。

Growth Rates of Pulmonary Carcinoid Tumors and Hamartomas.

机构信息

From the Brigham and Women's Hospital, Boston MA.

出版信息

J Comput Assist Tomogr. 2023;47(3):396-401. doi: 10.1097/RCT.0000000000001413. Epub 2023 Jan 14.

DOI:10.1097/RCT.0000000000001413
PMID:37185002
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10199237/
Abstract

BACKGROUND

Pulmonary nodule growth is often measured by volume doubling time (VDT), which may guide management. Most malignant nodules have a VDT of 20 to 400 days, with longer VDTs typically observed in indolent nodules. We assessed the utility of VDT in differentiating pulmonary carcinoids and hamartomas.

METHODS

A review was performed from January 2012 to October 2021 to identify patients with pathologic diagnoses and at least 2 chest computed tomography scans obtained 6 or more months apart. Visualization software was used to segment nodules and calculate diameter and volume. Volume doubling time was calculated for scans with 1-mm slices. For the remainder, estimated nodule volume doubling time (eVDT) was calculated using nodule diameter. Volume doubling times/eVDTs were placed into growth categories: less than 400 days; 400-600 days; and more than 600 days.

RESULTS

Sixty nodules were identified, 35 carcinoids and 25 hamartomas. Carcinoids were larger than hamartomas (median diameter, 13.5 vs 11.5 mm; P = 0.05). For carcinoid tumors, median VDT (n = 15) was 1485 days, and median eVDT (n = 32) was 1309 days; for hamartomas, median VDT (n = 8) was 2040 days and median eVDT (n = 25) was 2253 days. Carcinoid tumor eVDT was significantly shorter than hamartomas ( P = 0.03). By growth category, 1 of 25 hamartomas and 5 of 35 carcinoids had eVDT less than 400 days and 24 of 25 hamartomas and 27 of 35 carcinoids had eVDT more than 600 days. Of 4 carcinoid tumors with metastases, 2 had eVDT less than 400 days and 2 had eVDT more than 600 days.

CONCLUSIONS

Growth rate was not a reliable differentiator of pulmonary hamartomas and carcinoids. Slow growing carcinoids can metastasize. Radiologists should be cautious when discontinuing computed tomography follow-up based on growth rates alone.

摘要

背景

肺结节的生长通常通过倍增时间(VDT)来测量,这可能有助于指导治疗。大多数恶性结节的 VDT 为 20 至 400 天,惰性结节的 VDT 通常较长。我们评估了 VDT 在鉴别肺类癌和错构瘤方面的作用。

方法

对 2012 年 1 月至 2021 年 10 月期间进行的回顾性研究进行了评估,以确定至少有 2 次相隔 6 个月以上的胸部 CT 扫描且经病理诊断为患者。使用可视化软件对结节进行分割并计算直径和体积。对有 1 毫米切片的扫描进行 VDT 计算。对于其余扫描,使用结节直径计算估计的结节体积倍增时间(eVDT)。将体积倍增时间/eVDT 分为以下生长类别:小于 400 天;400-600 天;大于 600 天。

结果

共发现 60 个结节,其中 35 个为类癌,25 个为错构瘤。类癌比错构瘤大(中位直径,13.5 与 11.5 毫米;P=0.05)。15 个类癌肿瘤的中位 VDT 为 1485 天,32 个类癌肿瘤的中位 eVDT 为 1309 天;8 个错构瘤的中位 VDT 为 2040 天,25 个错构瘤的中位 eVDT 为 2253 天。类癌肿瘤的 eVDT 明显短于错构瘤(P=0.03)。按生长类别,25 个错构瘤中有 1 个和 35 个类癌中有 5 个的 eVDT 小于 400 天,25 个错构瘤中有 24 个和 35 个类癌中有 27 个的 eVDT 大于 600 天。4 个有转移的类癌肿瘤中,有 2 个的 eVDT 小于 400 天,有 2 个的 eVDT 大于 600 天。

结论

生长速度不是鉴别肺错构瘤和类癌的可靠指标。生长缓慢的类癌也可能发生转移。如果仅根据生长速度来停止 CT 随访,放射科医生应谨慎行事。

相似文献

1
Growth Rates of Pulmonary Carcinoid Tumors and Hamartomas.肺类癌肿瘤和错构瘤的生长速度。
J Comput Assist Tomogr. 2023;47(3):396-401. doi: 10.1097/RCT.0000000000001413. Epub 2023 Jan 14.
2
Is it possible to discriminate pulmonary carcinoids from hamartomas based on CT features?基于 CT 特征能否区分肺类癌和错构瘤?
Clin Imaging. 2020 Jun;62:49-56. doi: 10.1016/j.clinimag.2020.02.001. Epub 2020 Feb 8.
3
18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas.18F-FDG PET/CT 诊断支气管肺类癌与肺错构瘤。
Clin Nucl Med. 2016 Apr;41(4):263-7. doi: 10.1097/RLU.0000000000001114.
4
Volume Doubling Time of Pulmonary Carcinoid Tumors Measured by Computed Tomography.肺类癌肿瘤的 CT 体积倍增时间测量。
Clin Lung Cancer. 2022 Nov;23(7):e453-e459. doi: 10.1016/j.cllc.2022.06.006. Epub 2022 Jul 1.
5
A retrospective study of volume doubling time in surgically resected non-small cell lung cancer.手术切除的非小细胞肺癌体积倍增时间的回顾性研究。
Respirology. 2014 Jul;19(5):755-62. doi: 10.1111/resp.12311. Epub 2014 May 6.
6
Long-term follow-up of persistent pulmonary pure ground-glass nodules with deep learning-assisted nodule segmentation.基于深度学习的结节分割辅助技术对持续存在的肺部纯磨玻璃结节的长期随访。
Eur Radiol. 2020 Feb;30(2):744-755. doi: 10.1007/s00330-019-06344-z. Epub 2019 Sep 4.
7
Differential diagnostic value of F-FDG PET/CT in pulmonary carcinoids versus hamartomas.~F-FDG PET/CT 在肺类癌与错构瘤鉴别诊断中的价值。~
Acad Radiol. 2022 Feb;29 Suppl 2:S41-S46. doi: 10.1016/j.acra.2020.10.022. Epub 2020 Nov 9.
8
CT features of peripheral pulmonary carcinoid tumors.周围型肺类癌的 CT 特征。
AJR Am J Roentgenol. 2011 Nov;197(5):1073-80. doi: 10.2214/AJR.10.5954.
9
Best imaging signs identified by radiomics could outperform the model: application to differentiating lung carcinoid tumors from atypical hamartomas.通过影像组学识别出的最佳影像特征可能优于该模型:应用于鉴别肺类癌肿瘤与非典型错构瘤。
Insights Imaging. 2023 Sep 19;14(1):148. doi: 10.1186/s13244-023-01484-9.
10
CT- and computer-based features of small hamartomas.基于 CT 和计算机的小错构瘤特征。
Clin Imaging. 2011 Mar-Apr;35(2):116-22. doi: 10.1016/j.clinimag.2010.02.011.

引用本文的文献

1
Nomogram model for the diagnosis of solitary nodular pulmonary mucinous adenocarcinoma.用于诊断孤立性结节性肺黏液性腺癌的列线图模型。
Sci Rep. 2024 Aug 5;14(1):18085. doi: 10.1038/s41598-024-69138-4.
2
Risk and Time to Diagnosis of Lung Cancer in Incidental Pulmonary Nodules.偶然发现的肺部结节肺癌的风险和诊断时间。
J Thorac Imaging. 2024 Sep 1;39(5):275-280. doi: 10.1097/RTI.0000000000000768. Epub 2023 Nov 27.

本文引用的文献

1
Volume Doubling Time of Pulmonary Carcinoid Tumors Measured by Computed Tomography.肺类癌肿瘤的 CT 体积倍增时间测量。
Clin Lung Cancer. 2022 Nov;23(7):e453-e459. doi: 10.1016/j.cllc.2022.06.006. Epub 2022 Jul 1.
2
Cancer Risk in Nodules Detected at Follow-Up Lung Cancer Screening CT.随访肺癌筛查 CT 检测到的结节中的癌症风险。
AJR Am J Roentgenol. 2022 Apr;218(4):634-641. doi: 10.2214/AJR.21.26927. Epub 2021 Nov 10.
3
Well-Differentiated Bronchopulmonary Neuroendocrine Tumors: More Than One Entity.分化良好的支气管肺神经内分泌肿瘤:不止一种实体。
J Thorac Oncol. 2021 Nov;16(11):1810-1820. doi: 10.1016/j.jtho.2021.07.020. Epub 2021 Aug 2.
4
Differential diagnostic value of F-FDG PET/CT in pulmonary carcinoids versus hamartomas.~F-FDG PET/CT 在肺类癌与错构瘤鉴别诊断中的价值。~
Acad Radiol. 2022 Feb;29 Suppl 2:S41-S46. doi: 10.1016/j.acra.2020.10.022. Epub 2020 Nov 9.
5
The growth feature and its diagnostic value for benign and malignant pulmonary nodules met in routine clinical practice.常规临床实践中遇到的肺结节的生长特征及其对良恶性的诊断价值。
J Thorac Dis. 2020 May;12(5):2019-2030. doi: 10.21037/jtd-19-3591.
6
Volume Doubling Times of Lung Adenocarcinomas: Correlation with Predominant Histologic Subtypes and Prognosis.肺腺癌倍增时间:与主要组织学亚型和预后的相关性。
Radiology. 2020 Jun;295(3):703-712. doi: 10.1148/radiol.2020191835. Epub 2020 Mar 31.
7
Is it possible to discriminate pulmonary carcinoids from hamartomas based on CT features?基于 CT 特征能否区分肺类癌和错构瘤?
Clin Imaging. 2020 Jun;62:49-56. doi: 10.1016/j.clinimag.2020.02.001. Epub 2020 Feb 8.
8
Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.镓-68 生长抑素 PET/CT 初始显像对神经内分泌肿瘤患者诊断和治疗的影响。
J Surg Oncol. 2020 Mar;121(3):480-485. doi: 10.1002/jso.25812. Epub 2019 Dec 18.
9
Anatomical resections are superior to wedge resections for overall survival in patients with Stage 1 typical carcinoids.解剖性切除术在总生存方面优于楔形切除术,适用于 1 期典型类癌患者。
Eur J Cardiothorac Surg. 2019 Feb 1;55(2):273-279. doi: 10.1093/ejcts/ezy250.
10
Neuroendocrine Tumor Diagnosis and Management: Ga-DOTATATE PET/CT.神经内分泌肿瘤的诊断与治疗:Ga-DOTATATE PET/CT。
AJR Am J Roentgenol. 2018 Aug;211(2):267-277. doi: 10.2214/AJR.18.19881. Epub 2018 Jul 5.